Akari Therapeutics, Plc reported its financial results for the first quarter ended March 31, 2025, on May 15, 2025. The company announced a net loss from operations of approximately $3.7 million for the quarter, an improvement compared to a $5.6 million net loss for the same period in 2024.
Research and development expenses decreased significantly to $0.8 million for the three months ended March 31, 2025, down from approximately $2.3 million in the prior year. This reduction was primarily due to the decision to suspend the HSCT-TMA clinical stage program with nomacopan in May 2024.
General and administrative expenses also saw a decrease, falling to approximately $2.7 million from $3.7 million in the first quarter of 2024. This was mainly attributed to lower legal and professional fees related to the merger and reduced directors’ and officers’ insurance costs.
As of March 31, 2025, Akari held cash of approximately $2.6 million. The company also noted that net proceeds from its March 2025 offering, totaling approximately $6.0 million, included $4.0 million received in April 2025, which will extend its cash runway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.